Type 1 diabetes symptoms
type 1 diabetes symptoms signs clinical presentation

This clinical photograph set comprises two panels (A and B) comparing the presentation and resolution of a severe soft tissue infection on the right hand of a patient with type 2 diabetes. Panel A (Left) displays the palm and fingers during hospital admission, showing acute inflammatory signs localized to the middle finger. Findings include marked fusiform swelling, erythema, and a deep, irregular open wound over the proximal and middle phalanges with visible granulation tissue and purulent exudate. The distal aspect of the finger exhibits yellowish discoloration, suggesting impaired perfusion or advanced infection (pyogenic tenosynovitis). Panel B (Right) shows the same hand at a three-month follow-up after surgical debridement and targeted antibiotic therapy (Vancomycin). The image demonstrates complete resolution of edema and erythema, with a well-healed surgical scar on the volar surface of the middle finger and restoration of normal skin integrity and color. This comparison illustrates the clinical progression from an infected hand wound, complicated by Streptococcus gordonii, to successful recovery.

This set of clinical photographs demonstrates a bilateral and nearly symmetrical distribution of skin lesions on the anterior lower legs of a patient with uncontrolled type 2 diabetes. (a) An overview showing multiple, scattered, discrete vesicles and papules across the tibial surfaces. (b) A higher magnification view reveals tense, fluid-filled vesicles (3–7 mm) situated on an erythematous base, alongside lesions showing signs of umbilication and central crusting. (c) A close-up detail highlights the progression of the lesions from acute tense blistering to central crustations and the formation of fine, white, depressed (atrophic) scars in healed areas. The clinical presentation is characteristic of bullosis diabeticorum (diabetic bullae), illustrating the evolution from acute intraepidermal separation to scar formation in the context of poor metabolic control and impaired wound healing.

This clinical photograph displays two distinct, well-circumscribed skin lesions on the lower abdomen of a patient with type 1 diabetes, characteristic of Necrobiosis Lipoidica (NL). Panel (a) provides a wide view showing two oval-shaped plaques. Panel (b) offers a close-up macro view, highlighting the specific morphological features. The lesions demonstrate a central area of waxy, yellow-brown discoloration with visible cutaneous atrophy and telangiectasia. This central depression is sharply demarcated by a prominent, raised, and firm violaceous (purplish-red) border. The surrounding skin appears normal, emphasizing the clear margins of the inflammatory process. This visual presentation is a classic manifestation of NL, a granulomatous skin condition frequently associated with poor glycemic control. These educational images serve to illustrate the primary diagnostic features of the condition: atrophic center, yellowish hue, and peripheral violaceous elevation.

This clinical photographic timeline documents the progression and resolution of insulin-induced lipoatrophy in a 53-year-old female patient with type 1 diabetes. The series consists of eight panels arranged in two rows, comparing lateral and anterolateral views of the abdominal wall over four time points: November 2009, April 2010, June 2010, and July 2011. Initially, in November 2009, deep, well-demarcated cutaneous depressions and hollows are visible at previous insulin pump catheter insertion sites, indicating localized loss of subcutaneous adipose tissue. By April and June 2010, during and after low-dose prednisone therapy, these defects show progressive refilling and reduction in depth, with a return to a more even abdominal contour. The final images from July 2011 demonstrate clinical resolution of the lipoatrophic sites with some residual superficial skin wrinkling and laxity. The images illustrate the clinical presentation of lipoatrophy as a complication of subcutaneous insulin infusion and its response to corticosteroid treatment, emphasizing dermatological assessment in diabetic care.
"type 1 diabetes"[MeSH Terms] AND "symptoms"
| Symptom | Mechanism |
|---|---|
| Polyuria (frequent, large-volume urination) | Glucose spills into urine, drawing water with it osmotically |
| Polydipsia (extreme thirst) | Fluid loss from polyuria triggers thirst |
| Polyphagia (excessive hunger) | Cells cannot take up glucose without insulin - the body perceives starvation |
What's the difference between Type 1 and Type 2 diabetes symptoms?
| Feature | Type 1 | Type 2 |
|---|---|---|
| Onset of symptoms | Abrupt - days to weeks | Gradual - months to years |
| Typical age | Childhood / young adulthood | Over 40 (but rising in younger people) |
| Body habitus | Usually lean | Usually overweight/obese (but ~10% are not) |
| Classic triad (polyuria, polydipsia, polyphagia) | Present and pronounced | Present only with significant hyperglycemia (>180 mg/dL); often absent or mild |
| Weight loss | Rapid and prominent | May occur, but less dramatic |
| Fatigue | Yes | Yes (common but nonspecific) |
| Diagnosed how? | Usually symptomatic presentation | Often discovered on routine blood tests in an asymptomatic person |
| DKA risk | High - a common first presentation | Low (more likely to develop hyperosmolar hyperglycemic state) |
| Insulin levels | Very low or absent | Normal or high (but relatively insufficient) |
What tests confirm Type 1 vs Type 2 diabetes?
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting plasma glucose (FPG) | <100 mg/dL | 100-125 mg/dL | ≥126 mg/dL |
| 2-hour OGTT (75g oral glucose load) | <140 mg/dL | 140-199 mg/dL | ≥200 mg/dL |
| Random plasma glucose | - | - | ≥200 mg/dL + symptoms |
| HbA1c | <5.7% | 5.7-6.4% | ≥6.5% |
"The diagnosis of diabetes can be confirmed by the presence of two abnormal tests (fasting, 2-hour OGTT, or HbA1c) or by finding both unequivocal hyperglycemia (random plasma glucose >200 mg/dL) plus typical symptoms." - Goldman-Cecil Medicine
| Antibody | Notes |
|---|---|
| Anti-GAD65 (glutamic acid decarboxylase) | Highest sensitivity (~91%) as a single marker; more common in adults |
| Anti-IA-2 / ICA512 (islet antigen-2) | Tyrosine phosphatase on beta cell granules |
| Anti-ZnT8 (zinc transporter 8) | On surface of beta cell secretory granules |
| IAA (insulin autoantibodies) | More common in young children with T1DM |
| ICA (islet cell antibodies) | Older test; now largely replaced by the above |
| Purpose | Test(s) to Use |
|---|---|
| Confirm any diabetes | FPG, HbA1c, OGTT, random glucose |
| Distinguish T1 from T2 | C-peptide, pancreatic autoantibodies, fasting insulin |
| Monitor glucose control over time | HbA1c (every 3-6 months) |
| Detect DKA (T1 emergency) | Blood beta-hydroxybutyrate, anion gap, blood gas |
| Prediabetes screening | FPG 100-125, HbA1c 5.7-6.4%, OGTT 140-199 |